Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody Against Integrin avb8, in Patients With Advanced Solid Tumors

NCT06603844 is registered in ClinicalTrials.gov with Corbus Pharmaceuticals Inc. as lead sponsor.

NCT NCT06603844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06603844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody Against Integrin avb8, in Patients With Advanced Solid Tumors
Lead sponsor
Corbus Pharmaceuticals Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 4, 2024
Completion date
December 1, 2026
Enrollment
156 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor